176.57

0.26% 0.46

After Hours: 176.75 0.18 +0.10%

Quest Diagnostics Inc (DGX)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split Dividend History

Quest Diagnostics Inc stock is traded at $176.57, with a volume of 1.10M. It is up +0.26% in the last 24 hours and up +7.46% over the past month. Quest Diagnostics Inc is a leading independent provider of diagnostic testing, information, and services in the us. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk-assessment services, and information technology solutions.

Previous Close:

$176.11

Open:

$175.85

24h Volume:

1.10M

Relative Volume:

0.88

Market Cap:

$19.90B

Revenue:

$9.54B

Net Income/Loss:

$841.00M

P/E Ratio:

23.73

EPS:

7.44

Net Cash Flow:

$1.02B

1W Performance:

-0.93%

1M Performance:

+7.46%

6M Performance:

+13.04%

1Y Performance:

+28.94%

1-Day Range:

$175.25

$177.73

1-Week Range:

$175.25

$179.32

52-Week Range:

$135.47

$179.32

Quest Diagnostics Inc Stock (DGX) Company Profile

Name

Quest Diagnostics Inc

Sector

Healthcare (1154)

Industry

Diagnostics & Research (57)

Phone

(973) 520-2700

Address

500 PLAZA DRIVE, SECAUCUS

Employee

56,000

Twitter

@QuestDX

Next Earnings Date

2025-04-22

Latest SEC Filings

DGX's Discussions on Twitter

Compare DGX with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
DGX Quest Diagnostics Inc	176.57	19.90B	9.54B	841.00M	1.02B	7.44
TMO Thermo Fisher Scientific Inc	407.85	161.94B	42.90B	6.52B	6.72B	17.05
DHR Danaher Corp	193.09	142.65B	23.82B	3.77B	4.90B	5.15
IDXX Idexx Laboratories Inc	486.61	34.79B	3.93B	894.97M	837.70M	10.82
A Agilent Technologies Inc	107.52	30.67B	6.53B	1.26B	1.31B	4.35
IQV Iqvia Holdings Inc	153.30	27.00B	15.41B	1.37B	2.11B	7.50

Quest Diagnostics Inc Stock (DGX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-02-25	Initiated	Redburn Atlantic	Buy
Mar-04-25	Downgrade	Citigroup	Buy → Neutral
Jan-06-25	Upgrade	Leerink Partners	Market Perform → Outperform
Dec-17-24	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Dec-10-24	Resumed	Jefferies	Buy
Oct-23-24	Upgrade	Robert W. Baird	Neutral → Outperform
Aug-28-24	Resumed	Evercore ISI	In-line
Jul-10-24	Upgrade	Citigroup	Neutral → Buy
Feb-26-24	Initiated	Leerink Partners	Market Perform
Feb-07-24	Upgrade	Jefferies	Hold → Buy
Jan-03-24	Initiated	Barclays	Equal Weight
Dec-12-23	Upgrade	BofA Securities	Neutral → Buy
Jun-29-23	Initiated	Piper Sandler	Neutral
May-02-23	Downgrade	BofA Securities	Buy → Neutral
Apr-03-23	Upgrade	Citigroup	Sell → Neutral
Jan-23-23	Initiated	Evercore ISI	In-line
Nov-17-22	Downgrade	Citigroup	Neutral → Sell
Aug-22-22	Resumed	Morgan Stanley	Equal-Weight
Apr-04-22	Downgrade	Citigroup	Buy → Neutral
Feb-23-22	Downgrade	UBS	Buy → Neutral
Feb-02-22	Downgrade	Jefferies	Buy → Hold
Jan-28-22	Downgrade	Deutsche Bank	Buy → Hold
May-04-21	Upgrade	UBS	Neutral → Buy
Mar-12-21	Downgrade	Robert W. Baird	Outperform → Neutral
Oct-21-20	Upgrade	Argus	Hold → Buy
Jul-29-20	Upgrade	KeyBanc Capital Markets	Sector Weight → Overweight
Jul-14-20	Upgrade	BofA Securities	Neutral → Buy
Jun-09-20	Upgrade	Wells Fargo	Underweight → Equal Weight
Jun-02-20	Upgrade	Deutsche Bank	Hold → Buy
Apr-28-20	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Apr-27-20	Upgrade	Citigroup	Neutral → Buy
Apr-27-20	Upgrade	Wolfe Research	Underperform → Peer Perform
Mar-27-20	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Jan-08-20	Initiated	Wells Fargo	Underweight
Jan-07-20	Downgrade	Barclays	Overweight → Equal Weight
Dec-19-19	Upgrade	BofA/Merrill	Underperform → Neutral
Jul-15-19	Downgrade	Goldman	Neutral → Sell
Apr-02-19	Upgrade	Jefferies	Hold → Buy
Mar-18-19	Resumed	Credit Suisse	Neutral
Jan-31-19	Downgrade	Argus	Buy → Hold
Jan-17-19	Initiated	UBS	Neutral
Jan-03-19	Downgrade	BofA/Merrill	Neutral → Underperform
Dec-03-18	Downgrade	BofA/Merrill	Buy → Neutral
Nov-30-18	Downgrade	Goldman	Buy → Neutral

View All

Quest Diagnostics Inc Stock (DGX) Latest News

May 06, 2025

Take the Zacks Approach to Beat the Markets: ADMA Biologics, Limbach, Quest Diagnostics in Focus - MSN

May 06, 2025

May 03, 2025

Quest Diagnostics Stock: A Leader But Waiting For Better Price (NYSE:DGX) - Seeking Alpha

May 03, 2025

May 02, 2025

Quest Settles Fired Black Phlebotomist's Retaliation Suit - Law360

May 02, 2025

Apr 28, 2025

Fitch elevates Quest Diagnostics’ rating to ’BBB+’ with stable outlook By Investing.com - Investing.com Canada

Apr 28, 2025

Fitch elevates Quest Diagnostics’ rating to ’BBB+’ with stable outlook - Investing.com

Apr 28, 2025

Piper Sandler Adjusts Price Target on Quest Diagnostics to $200 From $180, Maintains Neutral Rating - marketscreener.com

Apr 28, 2025

Apr 26, 2025

Decoding Quest Diagnostics Inc (DGX): A Strategic SWOT Insight - GuruFocus

Apr 26, 2025

Apr 24, 2025

Here's How Much You Would Have Made Owning Quest Diagnostics Stock In The Last 5 Years - Benzinga

Apr 24, 2025

Truist Financial Keeps Their Hold Rating on Quest Diagnostics (DGX) - The Globe and Mail

Apr 24, 2025

Apr 23, 2025

These Analysts Boost Their Forecasts On Quest Diagnostics After Better-Than-Expected Q1 Earnings - Benzinga

Apr 23, 2025

Morgan Stanley Adjusts Quest Diagnostics Price Target to $182 From $172, Maintains Overweight Rating - marketscreener.com

Apr 23, 2025

Baird Adjusts Quest Diagnostics Price Target to $194 From $191, Maintains Outperform Rating - marketscreener.com

Apr 23, 2025

Jefferies Adjusts Quest Diagnostics Price Target to $195 From $190, Maintains Buy Rating - marketscreener.com

Apr 23, 2025

Quest Diagnostics (DGX) Sees Price Target Increase Following Str - GuruFocus

Apr 23, 2025

Mizuho Securities Adjusts Quest Diagnostics Price Target to $190 From $189 - marketscreener.com

Apr 23, 2025

Quest Diagnostics (DGX) Sees Price Target Increase Following Strong Q1 Results | DGX Stock News - GuruFocus

Apr 23, 2025

A Glimpse Into The Expert Outlook On Quest Diagnostics Through 12 Analysts - Benzinga

Apr 23, 2025

Quest Diagnostics Incorporated (NYSE:DGX) Q1 2025 Earnings Call Transcript - Insider Monkey

Apr 23, 2025

Truist Raises Price Target on Quest Diagnostics to $190 From $182, Keeps Hold Rating - marketscreener.com

Apr 23, 2025

Quest Diagnostics (DGX) Sees Price Target Boost from Barclays | - GuruFocus

Apr 23, 2025

Quest Diagnostics (DGX) Sees Price Target Boost from Barclays | DGX Stock News - GuruFocus

Apr 23, 2025

Quest Diagnostics (DGX) Stock Analysis: Unpacking the 5.32% Potential Upside for Investors - DirectorsTalk Interviews

Apr 23, 2025